Agenus Inc. (AGEN): Price and Financial Metrics
AGEN Price/Volume Stats
| Current price | $5.40 | 52-week high | $42.60 |
| Prev. close | $6.30 | 52-week low | $5.38 |
| Day low | $5.38 | Volume | 1,526,900 |
| Day high | $6.52 | Avg. volume | 572,109 |
| 50-day MA | $12.10 | Dividend yield | N/A |
| 200-day MA | $18.77 | Market Cap | 113.11M |
AGEN Stock Price Chart Interactive Chart >
Agenus Inc. (AGEN) Company Bio
Agenus Inc. engages in discovering and developing innovative treatments for patients with cancer and other diseases. The company was founded in 1994 and is based in Lexington, Massachusetts.
Latest AGEN News From Around the Web
Below are the latest news stories about AGENUS INC that investors may wish to consider to help them evaluate AGEN as an investment opportunity.
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority TagMerck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024. |
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall StreetThese two biotech stocks could be poised for a trend reversal. |
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC CandidateGSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093. |
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024LEXINGTON, Mass., December 20, 2023--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that data from an investigator sponsored trial (IST) evaluating botensilimab (BOT, multifunctional CTLA-4 immune activator) in combination with balstilimab (BAL, PD-1 antibody) in neoadjuvant colorectal cancer (CRC) will be presented at the upcoming ASCO-GI Meeting, to be held January 18 – 20, 2024 in San Francisco |
Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock UpBlueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%. |
AGEN Price Returns
| 1-mo | -49.03% |
| 3-mo | -52.08% |
| 6-mo | -69.81% |
| 1-year | -84.12% |
| 3-year | -89.69% |
| 5-year | -89.33% |
| YTD | -67.39% |
| 2023 | -65.50% |
| 2022 | -25.47% |
| 2021 | 1.26% |
| 2020 | -21.87% |
| 2019 | 71.01% |
Continue Researching AGEN
Here are a few links from around the web to help you further your research on Agenus Inc's stock as an investment opportunity:Agenus Inc (AGEN) Stock Price | Nasdaq
Agenus Inc (AGEN) Stock Quote, History and News - Yahoo Finance
Agenus Inc (AGEN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...